Soleno Therapeutics (NASDAQ:SLNO) Stock Rating Lowered by Wells Fargo & Company

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Several other equities research analysts have also recently commented on SLNO. Lifesci Capital cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Oppenheimer dropped their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. HC Wainwright cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $53.00 in a research report on Wednesday, April 8th. Cantor Fitzgerald cut shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the stock from $123.00 to $53.00 in a research report on Monday, April 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Soleno Therapeutics currently has an average rating of “Hold” and a consensus price target of $83.50.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock opened at $52.78 on Friday. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $39.99 and its two-hundred day moving average price is $47.32. Soleno Therapeutics has a 52 week low of $29.43 and a 52 week high of $90.32. The stock has a market cap of $2.72 billion, a PE ratio of 229.49 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after buying an additional 189 shares during the period. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics during the 2nd quarter worth about $25,000. Avanza Fonder AB raised its holdings in Soleno Therapeutics by 11.2% during the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after buying an additional 323 shares during the period. Principal Financial Group Inc. raised its holdings in Soleno Therapeutics by 11.9% during the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after buying an additional 340 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Soleno Therapeutics by 2.4% during the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after buying an additional 360 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Update on the company’s VYKAT XR observational (real‑world) study adds to the Prader‑Willi treatment narrative and may support longer‑term commercial expectations for VYKAT XR. Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
• Neutral Sentiment: Multiple investor‑rights firms are circulating notices about a pending securities class action and the May 5, 2026 lead‑plaintiff deadline; these outreach efforts are routine in securities litigation (they inform potential plaintiffs but do not by themselves change the merits of claims). SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors
• Negative Sentiment: Numerous law firms (Rosen, Hagens Berman, Bragar Eagel & Squire, Bronstein, Schall, Pomerantz, Faruqi, ClaimsFiler, etc.) have issued lead‑plaintiff/class action notices and at least one class action filing has been reported for the March 26–Nov 4, 2025 alleged class period—this increases legal risk, potential distraction, and uncertainty for shareholders. Bronstein, Gewirtz & Grossman LLC Urges Soleno Investors to Act
• Negative Sentiment: An analyst price‑target cut reported April 16 reduced the target by ~36%, signaling lowered analyst expectations and likely contributing downward pressure on sentiment despite the real‑world study update. Soleno Therapeutics (SLNO) price target decreased

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.